Clinical trial
Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different…
NCT00329576 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00329576 |
|---|---|
| Title | Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine |
| Official title | Evaluate the Anti-HBs Antibody Persistence, in Subjects Who Received GSK Biologicals' Preservative-free or Thiomersal-free Engerix™-B or Engerix™-B Containing Thiomersal, Approximately 5 to 6 Yrs Earlier |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Hepatitis B vaccine |
| Enrollment | 632 |
| Start date | May 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | May 24, 2006 |
| Last update posted | Sep 28, 2016 |
| Countries | Belgium, Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: